X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 42.0 -836.6 - View Chart
P/BV x 10.5 0.2 4,286.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
VENUS REMEDIES
Mar-16
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs6,015218 2,759.2%   
Low Rs3,70782 4,515.2%   
Sales per share (Unadj.) Rs1,236.9365.6 338.3%  
Earnings per share (Unadj.) Rs122.21.5 8,221.9%  
Cash flow per share (Unadj.) Rs129.037.9 340.1%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.2382.5 136.3%  
Shares outstanding (eoy) m21.2511.44 185.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.90.4 957.6%   
Avg P/E ratio x39.8101.0 39.4%  
P/CF ratio (eoy) x37.74.0 952.5%  
Price / Book Value ratio x9.30.4 2,377.5%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,2961,717 6,017.6%   
No. of employees `0003.01.0 289.8%   
Total wages/salary Rs m3,370324 1,038.8%   
Avg. sales/employee Rs Th8,891.84,100.7 216.8%   
Avg. wages/employee Rs Th1,140.0318.0 358.5%   
Avg. net profit/employee Rs Th878.316.7 5,269.9%   
INCOME DATA
Net Sales Rs m26,2844,183 628.4%  
Other income Rs m50420 2,509.5%   
Total revenues Rs m26,7894,203 637.4%   
Gross profit Rs m3,665812 451.6%  
Depreciation Rs m144417 34.6%   
Interest Rs m8380 2.1%   
Profit before tax Rs m4,01735 11,445.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,42118 7,850.8%   
Profit after tax Rs m2,59617 15,272.4%  
Gross profit margin %13.919.4 71.9%  
Effective tax rate %35.451.6 68.6%   
Net profit margin %9.90.4 2,430.3%  
BALANCE SHEET DATA
Current assets Rs m14,4462,771 521.4%   
Current liabilities Rs m4,7251,931 244.6%   
Net working cap to sales %37.020.1 184.3%  
Current ratio x3.11.4 213.1%  
Inventory Days Days51125 41.1%  
Debtors Days Days2054 36.4%  
Net fixed assets Rs m1,1135,328 20.9%   
Share capital Rs m213114 185.8%   
"Free" reserves Rs m10,8084,177 258.7%   
Net worth Rs m11,0764,376 253.1%   
Long term debt Rs m01,911 0.0%   
Total assets Rs m16,2418,428 192.7%  
Interest coverage x497.01.1 45,492.1%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.60.5 326.1%   
Return on assets %16.04.7 340.6%  
Return on equity %23.40.4 6,034.0%  
Return on capital %36.36.6 550.7%  
Exports to sales %0.60-   
Imports to sales %12.620.5 61.6%   
Exports (fob) Rs m162NA-   
Imports (cif) Rs m3,322858 387.1%   
Fx inflow Rs m2680-   
Fx outflow Rs m3,927858 457.6%   
Net fx Rs m-3,659-858 426.4%   
CASH FLOW
From Operations Rs m2,514469 536.3%  
From Investments Rs m-80029 -2,738.0%  
From Financial Activity Rs m-803-464 173.2%  
Net Cashflow Rs m91235 2,643.2%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   GSK PHARMA  NATCO PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 19, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS